0000000000245800

AUTHOR

Laurent Kodjikian

showing 9 related works from this author

Fiche d’information aux médecins : traitement de l’œdème maculaire diabétique

2015

Ophthalmologybusiness.industryMedicinebusinessJournal Français d'Ophtalmologie
researchProduct

Œdème maculaire diabétique : diagnostic et bilan pré-thérapeutique

2015

Pre treatmentmedicine.medical_specialtybusiness.industryDiabetic macular edema030209 endocrinology & metabolismDiabetic retinopathymedicine.diseaseWork-up03 medical and health sciencesOphthalmology0302 clinical medicineOphthalmology030221 ophthalmology & optometrymedicinebusinessMacular edemaJournal Français d'Ophtalmologie
researchProduct

Endophthalmitis after intravitreal injections: incidence, presentation, management, and visual outcome

2015

Purpose To report the incidence and characteristics of endophthalmitis after intravitreal injections of anti–vascular endothelial growth factor agents or corticosteroids and to describe the clinical and bacteriologic characteristics, management, and outcome of these eyes with acute endophthalmitis in France. Design Retrospective, nationwide multicenter case series. Methods From January 2, 2008 to June 30, 2013, a total of 316 576 intravitreal injections from 25 French ophthalmic centers were included. For each center, the number of intravitreal injections was determined using billing codes and the injection protocol was recorded. A registry and hospital records were reviewed to identify pat…

MaleVisual acuityfactor agentsVisual AcuityAngiogenesis InhibitorsEye Infections BacterialEndophthalmitisAntisepticRisk Factorscausative organismsrisk-factorsAged 80 and overEndophthalmitis[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyIncidence (epidemiology)IncidenceMiddle AgedAnti-Bacterial Agents[SDV.MHEP.OS] Life Sciences [q-bio]/Human health and pathology/Sensory OrgansIntravitreal InjectionsFemaleFrancePresentation (obstetrics)medicine.symptommetaanalysisAdultmedicine.medical_specialtymacular degenerationmedicine.drug_classRetinal DiseasesmedicineHumansranibizumab[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrgansGlucocorticoidsAgedRetrospective Studiesocular surfaceBacteriabusiness.industryRetrospective cohort studyantibiotic-prophylaxisEye infectionmedicine.diseaseConfidence intervalSurgeryVitreous BodyOphthalmologybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyoperating-roomendothelial growth-factor
researchProduct

Perioperative risk of bleeding with antithrombotic agents in macular surgery: a national, prospective, multicentre study

2020

International audience; Purpose To compare the risk of haemorrhagic complications in elective macular surgery between patients with no antithrombotic (AT) treatment (defined as patients with no history of AT therapy or who discontinued AT therapy) and patients who continued AT treatment during the surgery. Methods E-case report forms were prospectively recorded in a database before vitreoretinal surgery and 1 month after. Data on patient characteristics, surgical techniques, haemorrhagic complications and antithrombotic status were collected. Patients with retinal detachment, proliferative diabetic retinopathy and previous retinal haemorrhage were excluded. Results A total of 748 procedures…

Male[SDV]Life Sciences [q-bio]030204 cardiovascular system & hematologynoncardiac surgeryantiplateletsurgery0302 clinical medicineRisk FactorsAntithromboticMedicineProspective Studiesoral anticoagulantsguidelinesantithrombotic agenteducation.field_of_studyAnticoagulantvitreoretinalRetinal HemorrhageGeneral MedicineDiabetic retinopathy3. Good healthPopulation SurveillanceFemalemacular surgeryhaemorrhagehemorrhagemanagementmedicine.medical_specialtymedicine.drug_classPopulationPostoperative Hemorrhagemaintenance03 medical and health sciencesHumans[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrganseducationAgedbusiness.industryanticoagulantAnticoagulantsPerioperativeOdds ratioRetinal Perforationsmedicine.diseasedual antiplatelet therapyvitreoretinal surgeryConfidence intervalSurgerywarfarinOphthalmology030221 ophthalmology & optometrybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up StudiesRetinal haemorrhage
researchProduct

T054 - Development and validation of a risk-prediction nomogram for good functional response one year after treatment with anti-VEGF in naive-diabeti…

2018

National audience

[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology[SDV.MHEP.OS] Life Sciences [q-bio]/Human health and pathology/Sensory Organs[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrgansComputingMilieux_MISCELLANEOUS[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

2015-2016 - BCSC - Cours de sciences fondamentales et cliniques

2018

[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology[SDV.MHEP.OS] Life Sciences [q-bio]/Human health and pathology/Sensory Organs
researchProduct

Development and validation of a risk-prediction nomogram for poor functional response one year after treatment with anti-VEGF in naive-diabetic macul…

2018

International audience

[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology[SDV.MHEP.OS] Life Sciences [q-bio]/Human health and pathology/Sensory Organs[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrgansComputingMilieux_MISCELLANEOUS[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Efficacy and safety assessment of azithromycin 1.5% eye drops (azyter) in peri-operative antibio-prophylaxis for cataract surgery

2009

International audience; Introduction: Background: Endophthalmitis is still one of the most fearsome complications of cataract surgery. The most important pathogens causing post-operative phacoemulsification endophthalmitis are staphylococci. Methods: 85 patients were included in a phase II pilot study. Patients were divided in three groups, group 1 and 3 received either azithromycin 1.5% eye drops or placebo eye drops one day before surgery and for 2 days after surgery and group 2 received azithromycin 1.5% eye drops for 3 days after surgery. Treatments were administered twice a day: one drop in the morning and one in the evening. Bacterial samples were collected three times from the conjun…

[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology[SDV.MHEP.OS] Life Sciences [q-bio]/Human health and pathology/Sensory Organscataractclinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organsantibiotics/antifungals/antiparasitics[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Development and validation of a risk predictor nomogram for poor functional response one year after treatment with antiVEGF in naive diabetic macular…

2018

[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology[SDV.MHEP.OS] Life Sciences [q-bio]/Human health and pathology/Sensory Organs
researchProduct